CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
50-802

CHEMISTRY REVIEW(S)
NDA 50-802

Ziana (Clindamycin Phosphate and Tretinoin) Gel
1.2% and 0.025%

Dow Pharmaceutical Sciences

Jane L. Chang, Ph.D.

Review Chemist

Division of Dermatologic and Dental Drug Products
HFD-540
Table of Contents

Table of Contents .................................................................................................................. 2
Chemistry Review Data Sheet ................................................................................................. 3
The Executive Summary ......................................................................................................... 8
I. Recommendations ................................................................................................................ 8
   A. Recommendation and Conclusion on Approvability ....................................................... 8
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk
      Management Steps, if Approvable.................................................................................. 8
II. Summary of Chemistry Assessments .............................................................................. 8
    A. Description of the Drug Product(s) and Drug Substance(s) ........................................ 8
    B. Description of How the Drug Product is Intended to be Used ...................................... 10
    C. Basis for Approvability or Not-Approval Recommendation ........................................ 10
III. Administrative .................................................................................................................. 10
    A. Reviewer’s Signature: electronically signed in DFS ..................................................... 10
    B. Endorsement Block: electronically signed in DFS ....................................................... 10
    C. CC Block: entered electronically in DFS ..................................................................... 10
Chemistry Assessment ............................................................................................................ 11
I. Deficiencies Listed in 12/7/04 Action Letter .................................................................... 11
II. Additional Deficiencies Identified in This Review .......................................................... 23
III. Labeling and Package Insert .......................................................................................... 29

Appears This Way
On Original
Chemistry Review Data Sheet

1. NDA: 50-802
2. REVIEW #: 2
3. REVIEW DATE: 20-Sep-2006
4. REVIEWER: Jane L. Chang
5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Submission NDA 21-739</td>
<td>06-Feb-2004</td>
</tr>
<tr>
<td>(changed to NDA 50-802 as of November 25, 2004)</td>
<td></td>
</tr>
<tr>
<td>Amendment (SU)</td>
<td>20-Aug-2004</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendment (C)</td>
<td>03-Feb-2006</td>
</tr>
<tr>
<td>Amendment (AZ)</td>
<td>05-May-2006</td>
</tr>
<tr>
<td>Amendment (BC)</td>
<td>08-Aug-2006</td>
</tr>
<tr>
<td>Amendment (BL)</td>
<td>11-Aug-2006</td>
</tr>
<tr>
<td>Amendment (BC)</td>
<td>28-Aug-2006</td>
</tr>
<tr>
<td>Amendment (BC)</td>
<td>31-Aug-2006</td>
</tr>
<tr>
<td>Amendment (BL)</td>
<td>31-Aug-2006</td>
</tr>
<tr>
<td>Amendment (BC)</td>
<td>06-Sep-2006</td>
</tr>
<tr>
<td>Amendment (BL)</td>
<td>07-Sep-2006</td>
</tr>
<tr>
<td>Amendment (BL)</td>
<td>14-Sep-2006</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

<table>
<thead>
<tr>
<th>Name:</th>
<th>Dow Pharmaceutical Sciences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>1330A Redwood Way</td>
</tr>
<tr>
<td></td>
<td>Petaluma, CA 94954</td>
</tr>
<tr>
<td>Representative:</td>
<td>Barry M. Calvarese, MS</td>
</tr>
<tr>
<td></td>
<td>Vice President, Regulatory</td>
</tr>
<tr>
<td></td>
<td>and Clinical Affairs</td>
</tr>
<tr>
<td>Telephone:</td>
<td>707-793-2600</td>
</tr>
</tbody>
</table>
8. DRUG PRODUCT NAME/_CODE/TYPE:
   a) Proprietary Name: Ziana™
   b) Non-Proprietary Name: Clindamycin Phosphate and Tretinoin (all-trans retinoic acid) (combination drug)
   c) Code Name/# (ONDQA only): N/A
   d) Chem. Type/Submission Priority (ONDQA only):
      - Chem. Type: 3
      - Submission Priority: S

9. LEGAL BASIS FOR SUBMISSION: 505(b)(2)

10. PHARMACOL. CATEGORY: Antibiotic and Retinoid (combination drug)

11. DOSAGE FORM: Gel

12. STRENGTH/POTENCY: Clindamycin Phosphate, 1.2%; Tretinoin, 0.025%

13. ROUTE OF ADMINISTRATION: Topical

14. Rx/OTC DISPENSED: _X_Rx _OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____SPOTS product – Form Completed
   _X_ Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

   This is a combination drug product composed of two compendial drug substances, clindamycin phosphate and tretinoin (all-trans retinoic acid).

   **Clindamycin phosphate, USP**

   Chemical name: methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-a-D-galacto-octopyranoside 2-(dihydrogen phosphate)

   Molecular Formula: C_{18}H_{34}ClN_{2}O_{8}PS
   Molecular Weight: 504.97
   CAS Number: 24729-96-2
Chemistry Review Data Sheet

Chemical structure:

![Chemical Structure Image]

**Tretinoin, USP**

Chemical name: 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid (all-trans form)

USAN name: all-trans retinoic acid

Molecular Formula: \( C_{20}H_{28}O_2 \)

Molecular Weight: 300.44

CAS Number: 302-79-4

Chemical structure:

![Chemical Structure Image]

Appears This Way
On Original
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>July 26, 2006</td>
<td>By J. Chang. See below*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>June 8, 2004</td>
<td>By L. Huang for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>July 10, 2000</td>
<td>By M. Shih for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>August 23, 2006</td>
<td>See below**</td>
</tr>
</tbody>
</table>

*After this DMF was reviewed, the applicant withdrew the supplier in the 8/8/06 amendment.

**Two amendments (16-Jan-2001 and 05-Sep-2003) were submitted after the last review. The organization name change was the only change in the 05-Sep-2003 amendment, whereas the 16-Jan-2001 amendment included manufacturing sites and process changes. Review of these two amendments is not required as adequate information was provided in the NDA stated that the materials complied with 21 CFR 175:300 for the

---

See Attachment 4.3.9.1.2.1. Stated that the supplier for the material meets the requirements of 21 CFR 177.1520(c)(2.2). These are considered sufficient to establish safety of the material of construction for liquid-based topical dosage forms (e.g., gels, creams, etc) according to the FDA "Guidance for Industry, Container Closure Systems for Packaging Human Drugs and Biologics". Refer to section III.F.2 of the guidance.

1 Action codes for DMF Table:
1 – DMF Reviewed.
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

Appears This Way
On Original
B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IND</td>
<td>65,531</td>
<td>Clin-RA Gel (Clindamycin, 1%/Tretinoin, 0.025%)</td>
</tr>
</tbody>
</table>

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>8/30/2006</td>
<td>J. D Ambrogio</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>N/A, according to the current ONDQA policy*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Office of Drug Safety</td>
<td>Review underway**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Categorical exclusion (see review #1)</td>
<td>12/7/2004</td>
<td>Saleh Turujman</td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The analytical procedures and their validations were reviewed in review #1 by Dr. Saleh Turujman and found to be adequate. Methods validation packages will not be sent to FDA laboratories because the methods do not meet the “method validation request criteria” according to the current ONDQA policy that was announced on 1/12/05.

**Recommendation from Office of Drug Safety is not yet available at the time this review is completed. From CMC perspective, labeling information is adequate.
The CMC Review for NDA 50-802

_The Executive Summary_

I. Recommendations

A. Recommendation and Conclusion on Approvability

From a chemistry, manufacturing, and controls review perspective, this NDA may be approved.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

None

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

(1) Drug Product

The proposed drug product, Ziana™ Gel, is a translucent yellow topical gel containing a combination of two active pharmaceutical ingredients (APIs), clindamycin phosphate, 1.2% (equivalent to 1% clindamycin) and tretinoin (all-trans retinoic acid) 0.025%. Water comprises about of the vehicle, with glycerin agent is Carbopol 981 Other than Polysorbate 80 the remaining excipients are essentially agents (methylparaben and propylparaben).

Each of these two APIs is also a component of several approved combination drug products. However this is the first combination of these two APIs. The current submission provides for the treatment of acne vulgaris.

Acceptable specification has been provided to ensure product quality at release. The specification includes appearance, pH, viscosity, particle size, package integrity, microbial limits, identification and assay of the active ingredients, preservatives, and antioxidant, HPLC analysis of related substances, as well as antimicrobial effectiveness test.
Executive Summary Section

The drug product will be packaged in two commercial package size tubes, 30 g and 60 g, and a physician's sample container, 2 g tube.

Two years of real-time stability data have been provided for the primary stability batches. The data showed a decrease trend for clindamycin phosphate assay and increase trends for clindamycin and lincomycin-2-phosphate assays. The data support the proposed expiration dating period of 24 months for storage at 25 °C.

(2) Drug Substance

Clindamycin phosphate and tretinoin are two well-established compendial chemicals whose structures have been fully elucidated. All CMC information for and has been referred to their respective DMFs:

Both DMFs for clindamycin phosphate suppliers have been reviewed by this reviewer and found to be adequate. The applicant withdrew (DMF as the supplier in the 8/806 amendment. The DMF of the supplier was last reviewed by Liang Lii Huang and found to be adequate. These DMFs are currently adequate to support this NDA.

Both clindamycin phosphate and tretinoin are individually marketed in various formulations for the treatment of acne vulgaris, as indicated below.

Clindamycin phosphate, a lincosamide, which is a synthetic derivative of lincomycin, is a compendial antibiotic API used in several approved formulations, such as an injectable solution (NDA 50-441), a topical solution (NDA 50-537), a topical lotion (NDA 50-600), several topical gels (e.g., NDAs 50-615 and 50-782) and a topical foam (NDA 50-801). Except for NDA 50-441, which is formulated equivalent to 150 mg clindamycin/mL, all the afore-mentioned dosage forms use the same strength of clindamycin phosphate (equivalent to 1.0% clindamycin) proposed by the applicant.

Tretinoin is also a compendial drug substance which is used in several approved drug formulations. Examples include several topical creams (NDAs 19-963, 21-108, 19-049, 17-522, 17-340, 20-404 at concentrations of 0.05%, 0.02%, 0.025%, 0.05%, 0.1%, and 0.025%, respectively), several topical gels (NDAs 17-955, 17-579, 20-475, and 20-400 at concentrations of 0.01%, 0.025%, 0.04%, 0.025%, respectively), a topical solution (NDA 16-921, 0.05%), and an oral capsule (NDA 20-438, 10 mg). Tretinoin, all-trans retinoic acid, isomerizes easily under the influence of oxygen (air), heat, and light. Some of the cis-isomers are biologically active, e.g. 13-cis retinoic acid (USAN: isotretinoin, the API in Accutane). The manufacture of tretinoin drug products requires protection of the API from air and
Executive Summary Section

light during processing. Antioxidants are also generally required in the formulation of tretinoin containing products.

B. Description of How the Drug Product Is Intended to Be Used

This combination drug product is intended to be applied to the face once daily at bedtime for the treatment of acne vulgaris in patients 12 years and older. Exposure to sunlight, including sunlamps, should be minimized during the use of ZIANA™, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided.

Ziana™ Gel is to be stored at 25°C (77°F). When stored under the specified conditions, the drug product has an expiration dating period of two years. The drug product should be protected from light and freezing.

C. Basis for Approvability or Not-Approval Recommendation

The complete responses to the NA letter addressed all the CMC issues adequately to ensure the drug product’s identity, strength, quality, purity, potency, and stability. All manufacturing and testing facilities were found to be acceptable by the Office of Compliance. Therefore, from a CMC standpoint, this new drug application may be approved.

III. Administrative

A. Reviewer’s Signature: electronically signed in DFS

B. Endorsement Block: electronically signed in DFS

C. CC Block: entered electronically in DFS

Appears This Way
On Original
Page(s) Withheld

✔️ Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Jane Chang  
9/20/2006 05:48:56 PM  
CHEMIST

Moo-Jhong Rhee  
9/22/2006 01:18:17 PM  
CHEMIST  
Chief, Branch III

Appears This Way  
On Original
Initial Quality Assessment
Branch III
Pre-Marketing Assessment Division II

OND Division: Division of Dermatology and Dental Products
NDA: 50-802
Applicant: Dow Pharmaceutical Sciences, Inc.
Stamp Date: May 8, 2006
PDUFA Date: November 8, 2006
Trademark: Clin RA Gel
Established Name: Clindamycin and Tretinoin
Dosage Form: Gel
Route of Administration: Topical
Indication: Acne vulgaris

PAL: Shulin Ding

ONDQA Fileability: YES ☒ NO ☐
Comments for 74-Day Letter ☒ ☐

Summary and Critical Issues:

A. Summary
   This NDA was resubmitted in response to the deficiencies identified in the CMC review #1. It is considered to be a complete response. However, some of the responses are inadequate and are listed in Section C.

B. Critical issues for review
   See Section C.

C. Comments for 74-Day Letter
   1. ☐
   2. ☐
D. Recommendation:

This NDA is fileable from a CMC perspective. The comments for 74-day letter should be sent to the applicant.

(See attached electronic signature page)

Jane L. Chang, Ph.D.                   Date
Review Chemist

(See attached electronic signature page)

Moo-Jhong Rhee, Ph.D.                   Date
Branch Chief
NDA 50-802

Tradename (Clindamycin, 1%; Tretinoin, 0.025%) Gel

Dow Pharmaceutical Sciences

Saleh A. Turujman, Ph.D.
Division of Dermatologic and Dental Drug Products
HFD-540

Appears This Way
On Original
Table of Contents

Table of Contents ................................................................. 2

Chemistry Review Data Sheet ..................................................... 7

The Executive Summary .............................................................. 11

I. Recommendations .................................................................... 11
   A. Recommendation and Conclusion on Approvability ...................... 11
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable .......................... 11

II. Summary of Chemistry Assessments ........................................... 11
   A. Description of the Drug Product and Drug Substances .................. 11
   B. Description of How the Drug Product is Intended to be Used ............ 12
   C. Basis for Approvability or Not-Approval Recommendation ............... 13

III. Administrative ........................................................................ 16
   A. Reviewer’s Signature ............................................................ 16
   B. Endorsement Block ............................................................. 16
   C. CC Block ........................................................................ 16

Chemistry Assessment ................................................................. 17

I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body of Data ......................................................... 17

S DRUG SUBSTANCES ................................................................. 17

Clindamycin phosphate, USP ..................................................... 17

S.1.A General Information .......................................................... 17
   S.1.A.1 Nomenclature .............................................................. 17
   S.1.A.2 Structure .................................................................... 18
   S.1.A.3 General Properties ...................................................... 18

S.2.A Manufacture of Clindamycin phosphate ................................... 18
   S.2.A.1 Manufacturers ............................................................. 18
A.2 Adventitious Agents Safety Evaluation .................................................. 72
A.3 Novel Excipients .................................................................................... 72

R REGIONAL INFORMATION ..................................................................... 72
R1 Executed Batch Records ....................................................................... 72
R2 Comparability Protocols ....................................................................... 72
R3 Methods Validation Package ................................................................ 72

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 .. 72
A. Labeling & Package Insert ..................................................................... 72
B. Environmental Assessment Or Claim Of Categorical Exclusion .......... 72

III. List of Deficiencies to Be Communicated to the Applicant .............. 73
Appendix 1 ............................................................................................... 76
Appendix 1 (cont'd) .................................................................................. 77
Appendix 1 (cont'd) .................................................................................. 78
Appendix 1 (cont'd) .................................................................................. 79

Appears This Way
On Original
Chemistry Review Data Sheet

1. NDA: 50-802 (Original submission given NDA Number 21-739)

2. REVIEW #: 1

3. REVIEW DATE: 12/6/04

4. REVIEWER: Saleh A. Turujman, Ph.D.

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Submission NDA 21-739</td>
<td>6 February 2004</td>
</tr>
<tr>
<td>(Changed to NDA 50-802 as of November 25, 2004)</td>
<td>20 August 2004</td>
</tr>
<tr>
<td>NDA 21-739/N-001</td>
<td></td>
</tr>
<tr>
<td>(Changed to NDA 50-802 as of November 25, 2004)</td>
<td></td>
</tr>
</tbody>
</table>

6. SUBMISSIONS BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Submission NDA 21-739</td>
<td>6 February, 2004</td>
</tr>
<tr>
<td>(Changed to 50-802 as of November 25, 2004)</td>
<td>20 August 2004</td>
</tr>
<tr>
<td>NDA 21-739/N-001</td>
<td></td>
</tr>
<tr>
<td>(Changed to NDA 50-802 as of November 25, 2004)</td>
<td></td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

<table>
<thead>
<tr>
<th>Name:</th>
<th>Dow Pharmaceutical Sciences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>1330A Redwood Way</td>
</tr>
<tr>
<td>Petaluma, CA 94954</td>
<td></td>
</tr>
<tr>
<td>Representative:</td>
<td>Clawson C. Bowman, JD., RAC</td>
</tr>
<tr>
<td>Vice President, Regulatory Affairs</td>
<td></td>
</tr>
<tr>
<td>Telephone:</td>
<td>(707) 793-2600</td>
</tr>
</tbody>
</table>

8. DRUG PRODUCT NAME/CODE/TYPE:

a) Proprietary Name: Trade name to be determined (Clin-RA, the proposed trade name, not acceptable to DMETS)

b) Non-Proprietary Name (USAN): Clindamycin Phosphate and Tretinoin (all-trans Retinoic Acid) (combination drug)
9. LEGAL BASIS FOR SUBMISSION: 505(b)(2)

10. PHARMACOL. CATEGORY: Antibiotic and Retinoid (combination drug)

11. DOSAGE FORM: Gel

12. STRENGTH/POTENCY: Clindamycin, 1%; Tretinoin, 0.025%

13. ROUTE OF ADMINISTRATION: Topical

14. Rx/OTC DISPENSED: ___X_Rx ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    _____SPOTS product – Form Completed
    ___X___Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:
   This is a combination drug product composed of two compendial drug substances, clindamycin phosphate and tretinoin (all-trans retinoic acid).

   **Clindamycin phosphate, USP**
   The chemical name is methyl-7-chloro-6,7,8-trIDEOxy-6-(1-methyl-4-trans-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate)
   Molecular FormulA: C₃₈H₅₄ClN₅O₉P₇S
   Molecular Weight: 504.97
   CAS Number: 24729-96-2,
   The chemical structure is shown below.

![Chemical Structure](image)
Tretinoin, USP
The chemical name is 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid (all-trans form). The USAN name is all-trans retinoic acid.
Molecular Formula: C_{26}H_{28}O_{2}; Molecular Weight: 300.44
CAS Number: 302-79-4.
The chemical structure is shown below.

17. RELATED/SUPPORTING DOCUMENTS:
A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>DMF HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS²</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>September 8, 2003</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>November 23, 2004</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Inadequate</td>
<td>March 12, 2004</td>
<td>See below*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Inadequate</td>
<td>August 15, 2003</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>October 7, 2003</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>July 10, 2000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Adequate</td>
<td>June 5, 2002</td>
<td></td>
</tr>
</tbody>
</table>

* In the initial review of March 24, 2004 the OGD reviewer determined that DMF Type was inadequate. More recently, however, the ONDC reviewer found DMF to be adequate. Hence, the DMF was accepted, and DMF was therefore also adequate (acceptable).

¹ Action codes for DMF Table:
   1 – DMF Reviewed.
   Other codes indicate why the DMF was not reviewed, as follows:
   2 – Type 1 DMF
   3 – Reviewed previously and no revision since last review
   4 – Sufficient information in application
   5 – Authority to reference not granted
   6 – DMF not available
   7 – Other (explain under "Comments")

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT TYPE</th>
<th>APPLICATION NUMBER</th>
<th>HOLDER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IND</td>
<td>65,531</td>
<td>Dow Pharmaceutical Sciences</td>
<td>Clin-RA Gel (Clindamycin, 1%/Tretinoin, 0.025%)</td>
</tr>
</tbody>
</table>

18. STATUS:

**ONDC:**

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES* (Drug substance: Manufacturer/Packager/Tester:</td>
<td>Acceptable</td>
<td>3 March 2004</td>
<td>Janine D'Ambrogio</td>
</tr>
<tr>
<td>EES* (Drug substance: Manufacturer/Packager/Tester:</td>
<td>Acceptable</td>
<td>2 March 2004</td>
<td>Janine D'Ambrogio</td>
</tr>
<tr>
<td>EES* (Drug substance: Manufacturer/Packager/Tester:</td>
<td>Acceptable</td>
<td>15 April 2004</td>
<td>Shawnte L. Adams</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(Applicant initially provided</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>the incorrect address, hence</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>initial decision on March 4,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2004 of &quot;withhold&quot; and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>comment &quot;facility not doing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>function&quot;</td>
</tr>
<tr>
<td>EES* (Drug product: Manufacturer/Packager/Tester:</td>
<td>Acceptable</td>
<td>5 March 2004</td>
<td>Janine D'Ambrogio</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Deferred</td>
<td>N/A</td>
<td>Linda M. Wisniewski, R.N.</td>
</tr>
<tr>
<td>DMETS</td>
<td>&quot;Clin-RA&quot; Gel Not acceptable</td>
<td>5 October 2004</td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td>Categorical Exclusion</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Microbiology</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* See Appendix 1 for EES report
The Chemistry Review for NDA 50-802

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability
   The recommendation for this NDA, after discussion with the Team Leader, is Approvable from a chemistry, manufacturing and controls standpoint.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable
   None recommended.

II. Summary of Chemistry Assessments

A. Description of the Drug Product and Drug Substances
   The proposed drug product is a translucent yellow topical gel containing a combination of two active pharmaceutical ingredients (APIs), clindamycin phosphate, 1.2% (equivalent to 1% clindamycin) and tretinoin (all-trans retinoic acid) 0.025%.

   Water comprises about of the vehicle, with glycerin ___ of the ___. The other agent is Carbopol 981. Other than Polysorbate 80, a __ of the remaining excipients are essentially __ agents (Methylparaben and Propylparaben), and __ agents and an __. The drug product will be packaged in two commercial package size tubes, 30 g and 60 g, and a physician’s sample container, 2 g tube.

   Clindamycin phosphate and tretinoin are two well-established compendial chemicals whose structures have been fully elucidated. They are listed in USAN and in the Merck Index. The DMF of both drug substance suppliers have been previously reviewed and found to be adequate. Both clindamycin phosphate and tretinoin are individually marketed in various formulations for the treatment of acne vulgaris, as indicated below.

   Clindamycin phosphate, a lincosamide, which is synthetically a derivative of lincomycin, is a compendial antibiotic API used in several approved formulations, such as a sterile solution (NDA 50-441), a topical solution (NDA 50-537), a topical lotion (NDA 50-600), several topical gels (e.g., NDA 50-615, NDA 50-782) and a (NDA __). All the afore-mentioned dosage forms use the same strength of clindamycin phosphate (equivalent to 1.0% clindamycin) proposed by the applicant.
Tretinoin is also a compendial drug substance which is used in several approved drug formulations. Examples include several topical creams (NDA 19-963, NDA 21-108, NDA 19-049, 17-522, NDA 17-340, NDA 20-404 at concentrations of 0.01%, 0.025%, 0.04%, 0.025%), several topical gels (NDA 17-955, NDA 17-579, NDA 20-475, NDA 20-400 at concentrations of 0.01%, 0.025%, 0.04%, 0.025%), a topical solution (NDA 16-921, 0.05%), and an oral capsule (NDA 20-438, 10 mg). Tretinoin, all-trans retinoic acid, is the most stable of several isomers of retinoic acid, all of which isomerize easily under the influence of oxygen (air), heat, light, acid, or sonication. Some of these isomers are biologically active, e.g. 13-cis retinoic acid (USAN: isoretinoin, the API in Accutane). The manufacture of tretinoin drug products requires the shielding of the API from air and light during processing. Antioxidants are also generally required in the formulation of tretinoin containing products, which have to be protected from exposure to air, heat and light.

Each of these two APIs is also a component of several approved combination drug products. However this is the first combination of these two APIs. The current submission provides for the treatment of acne vulgaris. In addition to clindamycin (gel, solution, lotion, swab), prescription topical treatments indicated for acne vulgaris include erythromycin (gel, ointment, solution, swab), benzoyl peroxide gel, benzoyl peroxide and erythromycin gel, benzoyl peroxide and clindamycin gel, tretinoin (gel, cream, solution), adapalene (gel and cream) and tazarotene (gel and cream).

Clin-RA Gel, the proprietary name initially proposed for this drug product was found to be unacceptable by DMETS.

B. Description of How the Drug Product is Intended to be Used
This combination drug product is proposed for the treatment of acne vulgaris in patients 12 years and older. It is intended for a once daily application. The two APIs in this drug product target a different aspect of the acne pathogenic pathway. In general, physicians recommend a twofold approach for acne treatment: application of a topical antimicrobial, such as clindamycin phosphate, in the morning, and a topical tretinoin formulation in the evening. The proposed drug product would provide for a dual-action product with once daily application. However, the recommendation for this combination drug product is "Not Approvable" because of efficacy concerns (the contribution of each component to efficacy was not adequately demonstrated; refer to the clinical review for details). The clinical reviewer expressed no safety concerns.

The applicant proposes an expiration dating period of 24 months, which is supported by 12 months of long-term stability data (25°C/60% RH) for primary stability batches, 18 months of long-term-stability data for primary stability batch, 12 months of stability data under intermediate conditions (30°C/60% RH), and 6 months of stability data at 40°C/75% RH. Regression analysis is also provided. Since the
recommendation for this NDA is "Not Approvable" from a clinical standpoint, the applicant should be requested to provide the available stability data for the [entire] proposed shelf life of the drug product, when this NDA is resubmitted, as indicated in Section III. "List Of Deficiencies To Be Communicated" of this review.

Review of the labeling is deferred since this application is not approved from a clinical standpoint.

C. Basis for Approvability or Not-Approval Recommendation

After evaluation for GMP compliance, all manufacturing and testing facilities were found to be acceptable. However, was not submitted for inspection. Instead, a letter of cGMP compliance for the is provided, presumably in lieu of an FDA inspection. However, self-certification is not an acceptable alternative to an inspection by FDA. It is not an obstacle to approval, since the site could be withdrawn until it is inspected by the Agency.

The applicant does not identify critical points or critical steps in the manufacturing process. The applicant was reminded at the pre-NDA meeting on October 1, 2003, of such a requirement. The applicant should be requested to provide the results of the est. This is also not an approvability issue, because we have not insisted on such information from previous gel manufacturers. The information is now being explored as a way of guiding the applicant through process quality control (quality by design).

The following issues should be addressed in the resubmission:
III. Administrative
   A. Reviewer's Signature

   B. Endorsement Block
      Chemist Name/Date: Saleh A. Turujman, Ph.D./4 December 2004
      Chemistry Team Leader Name/Date: Ramesh Sood, Ph.D./
      Project Manager Name/Date: Jacqueline Smith

   C. CC Block
      Cc: NDA 21-739
      HFD-540/Division File
      HFD-540/830/Chem/SATurujman
      HFD-830/ChemTL/RSood
      HFD-540/ProjMgr/JSmith
      HFD-540/MedOff/BCarr
      HFD-540/Pharm/JMerrill
      HFD-540/BioPharm/EBashaw
      HFD-540/Biometrics/SLee
Page(s) Withheld

✓ Trade Secret / Confidential (b4)

Draft Labeling (b4)

Draft Labeling (b5)

Deliberative Process (b5)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Saleh Turujman
12/7/04 02:52:33 PM
CHEMIST

For your concurrence

Ramesh Sood
12/7/04 02:55:28 PM
CHEMIST

Appears This Way
On Original